All case studies

Highlights

We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.

Proactive patient retention strategy in a GLP-1 RA trial

Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.

A small biotech success story

A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.

FSP partnership - sustained efficiency and ongoing innovation

The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.

By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.

All case studies

Filter our case studies by categories, selecting amongst our broad range of solutions.

Exceeding late phase study recruitment goals

Over 19 days, ICON conducted a focused site engagement programme to increase patient screening and accelerate enrolment of a late phase multinational, multicentre study to evaluate a treatment for pulmonary disease.

Re-adjudicating a respiratory and cardiovascular trial during COVID-19

The FDA advised the trial to re-adjudicate so that the study accounted for the effects of COVID-19 on the trial outcomes. To ensure that the trial data would be submitted to the FDA as scheduled, ICON needed to coordinate re-adjudication of 700 endpoints within a compressed three-month timeline.

Automating EDC user access for improved trial efficiency

This case study demonstrates how ICON automated EDC user access management using API integrations and workflow automation, enhancing efficiency, security, compliance, and scalability in clinical trials while reducing costs and delays.

Enhancing the impact of scientific posters

The ICON global medical communications group worked with a large pharmaceutical company to identify ways to engage the congress audience and expand the impact of their scientific presentations at a large international meeting.

Pain proof of concept

ICON had he objective to develop a smartwatch mobile app combination that can be used to alert patients, and physicians and drug development teams to physical behaviours that may exacerbate patients’ pain.

Allergic rhinitis

A Biotech client contracted ICON to conduct a Phase III study that was a double-blinded, randomised, multinational, multicentre, placebo-controlled trial.

Triple negative breast cancer

A large, multinational pharmaceutical company needed to better understand patient perspectives to optimize protocol and study design and operationalise a study for TNBC.

Successes in phase 2 autologous cellular therapy Oncology programme

ICON was awarded two early development cancer immunotherapy studies from a biotherapeutic company for a potentially ground¬breaking autologous cellular therapy in the treatment of two tumour types.

Study in type 1 diabetes patients

Sponsor proposed a randomized, open-label, multi-centre, parallel-group study comparing the safety and efficacy of STUDY DRUG with Novolog in type 1 diabetes (T1D) patients.

Severe COPD phase III case study

A sponsor conducting an international Phase III program of two double-blind, randomised studies consulted ICON’s respiratory experts for assistance in patient enrolment, and study planning and monitoring.

Complex, early-phase study in Huntington’s disease

ICON was contracted to conduct an early-phase clinical trial in Huntington’s disease across 12 countries and 53 sites.

Long-term follow-up study for rare disease gene therapy

ICON provided full-service support to a large biotech company in two global Phase 3 trials for a gene therapy product treating spinal muscular atrophy (SMA), a rare but serious condition causing muscle wasting and weakness.

Solutions case studies

Our solutions span the entire lifecycle of product development and can be adapted to suit small local trials or large global programs. Explore our work in the different aspects of our solutions.

Let's collaborate

Discover how ICON's expertise transforms clinical trials.

Blogs

Stay informed with ICON's expert insights on clinical trials, regulatory changes, and industry trends. Our blogs provide practical advice, innovative solutions, and thought leadership from global experts.

News

Stay updated with our latest news on partnerships, financial results, technological advancements, and industry insights.

Insights

Explore ICON's expert analysis and practical advice on the latest operational, regulatory, technological and economic challenges in clinical research. Our insights provide thought leadership and innovative solutions to transform trials.

Case studies

Highlights

Proactive patient retention strategy in a GLP-1 RA trial

A small biotech success story

FSP partnership - sustained efficiency and ongoing innovation

All case studies

Exceeding late phase study recruitment goals

Re-adjudicating a respiratory and cardiovascular trial during COVID-19

Automating EDC user access for improved trial efficiency

Enhancing the impact of scientific posters

Pain proof of concept

Allergic rhinitis

Triple negative breast cancer

Successes in phase 2 autologous cellular therapy Oncology programme

Study in type 1 diabetes patients

Severe COPD phase III case study

Complex, early-phase study in Huntington’s disease

Long-term follow-up study for rare disease gene therapy

Solutions case studies

Let's collaborate

Blogs

News

Insights